MAO-inhibitors in Parkinson's Disease

Monoamine oxidase inhibitors (MAO-I) belong to the earliest drugs tried in Parkinson's disease (PD). They have been used with or without levodopa (L-DOPA). Non-selective MAO-I due to their side-effect/adverse reaction profile, like tranylcypromine have limited use in the treatment of depression...

Descripción completa

Detalles Bibliográficos
Autores principales: Riederer, Peter, Laux, Gerd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society for Brain and Neural Science 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3213739/
https://www.ncbi.nlm.nih.gov/pubmed/22110357
http://dx.doi.org/10.5607/en.2011.20.1.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3213739/
https://www.ncbi.nlm.nih.gov/pubmed/22110357
http://dx.doi.org/10.5607/en.2011.20.1.1

Ejemplares similares